Impaired survival of patients with non donor-specific anti-HLA antibodies before HLA-mismatched allogeneic stem cell transplantation - 04/09/24
Abstract |
Background |
While the detrimental role of donor-specific anti-HLA antibodies (DSAs) is well-described in the setting of hematopoietic stem cell transplantation (HSCT), few studies focus on non donor-specific ones and with controversial results.
Methods |
We here report our monocenter experience on 64 adult patients receiving allogeneic HSCT from a HLA-mismatched donor between 2014 and 2022 who were tested for the presence of anti-HLA antibodies before transplant, focusing on fifteen patients with non donor-specific anti-HLA antibodies.
Results |
The survival of patients with non donor-specific anti-HLA antibodies was inferior with respect to patients without anti-HLA antibodies and similar to patients with DSAs. Median survival of patients with non donor-specific anti-HLA antibodies was 21 months (95 % CI: 9–42) vs. 61 months (95 % CI: 17–77) among the anti-HLA antibody-negative patients, with a significantly higher mortality incidence rate ratio (3.3 times-fold greater, p = 0.01). No pattern of death causes was found
Conclusions |
In this monocenter series of HLA-mismatched HSCTs, impaired survival was observed in adult patients having non donor-specific anti-HLA antibodies before transplant, similar to those with DSAs. Our findings support those antibodies as a negative predictive factor even if they are not directed against the donor, thus warranting further investigation on larger cohorts.
Le texte complet de cet article est disponible en PDF.Keywords : Anti-HLA antibodies, HLA-mismatched, Hematopoietic stem cell transplantation, Survival
Plan
Vol 72 - N° 3
Article 103464- septembre 2024 Retour au numéro
Article précédent
- In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide
- Emine Begum Gencer, Hasan Yalim Akin, Selami Kocak Toprak, Eylul Turasan, Mahsa Yousefzadeh, Pinar Yurdakul-Mesutoglu, Murat Cagan, Mehmet Murat Seval, Doruk Cevdi Katlan, Klara Dalva, Mehmet Sinan Beksac, Meral Beksac
- Extracorporeal membrane oxygenation (ECMO) during aplasia: A bridge towards myopericarditis recovery after autologous hematopoietic stem cell transplant for systemic sclerosis and recent Coronarovirus disease (COVID-19) vaccination
- Carlotta Cacciatore, Mathilde Baudet, Estelle Jean, Simona Presente, Marylou Para, Romain Sonneville, Dimitri Arangalage, Nassim Ait Abdallah, Flore Sicre de Fontbrune, Pedro Henrique Prata, Benjamin Crichi, Baptiste Hervier, Nathalie Parquet, Gilles Soulat, Elie Mousseaux, Richard K Burt, Dominique Farge
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?